Table II.
Summary of primary myeloma treatments in the as-randomized population.
| 340 mg/m2 | 175 mg/m2 | 50 mg/m2 | Total | |
|---|---|---|---|---|
| n = 8 | n = 8 | n = 6 | N = 22 | |
| Time since original diagnosis (months) | ||||
| N | 8 | 8 | 5 | 21 |
| Median | 62·5 | 95·0 | 59·0 | 81·0 |
| Range | 31–124 | 37–111 | 40–140 | 31–140 |
| Prior SCT, n (%) | ||||
| Allogeneic | 1 (13) | 0 | 1 (17) | 2 (9) |
| Autologous | 5 (63) | 6 (75) | 5 (83) | 16 (73) |
| Not considered eligible at any time since diagnosis for SCT | 2 (25) | 2 (25) | 0 | 4 (18) |
| Total number of prior myeloma regimens | ||||
| N | 8 | 8 | 6 | 22 |
| Median (range) | 4·0 (3–8) | 6·5 (4–10) | 4·5 (4–11) | 5·0 (3–11) |
| Chemotherapeutic agents, n (%) | ||||
| Bortezomib | 8 (100) | 8 (100) | 6 (100) | 22 (100) |
| Lenalidomide | 8 (100) | 8 (100) | 6 (100) | 22 (100) |
| Thalidomide | 7 (88) | 8 (100) | 6 (100) | 21 (96) |
| Dexamethasone | 7 (88) | 8 (100) | 6 (100) | 21 (96) |
| Melphalan | 6 (75) | 7 (88) | 4 (67) | 17 (77) |
| Cyclophosphamide | 6 (75) | 7 (88) | 3 (50) | 16 (73) |
| Doxorubicin | 4 (50) | 5 (63) | 3 (50) | 12 (55) |
| Best response to most recent regimen, n (%) | ||||
| Complete response | 1 (13) | 0 | 0 | 1 (5) |
| VGPR | 2 (25) | 1 (13) | 0 | 3 (14) |
| Partial response | 1 (13) | 1 (13) | 0 | 2 (9) |
| Minimal response | 1 (13) | 2 (25) | 3 (50) | 6 (27) |
| Stable disease | 1 (13) | 3 (38) | 1 (17) | 5 (23) |
| Progressive disease | 2 (25) | 1 (13) | 2 (33) | 5 (23) |
| Reason for most recent discontinuation, n (%) | ||||
| Progressive disease | 5 (63) | 5 (63) | 5 (83) | 15 (68) |
| Intolerance | 2 (25) | 0 | 0 | 2 (9) |
| Other | 1 (13) | 3 (38) | 1 (17) | 5 (23) |
SCT, stem cell transplant; VGPR, very good partial response, according to the IMWG uniform criteria (2006).